High baseline Tie1 level predicts poor survival in metastatic breast cancer

Show full item record



Permalink

http://hdl.handle.net/10138/306047

Citation

Tiainen , L , Korhonen , E A , Leppänen , V-M , Luukkaala , T , Hämäläinen , M , Tanner , M , Lahdenperä , O , Vihinen , P , Jukkola , A , Karihtala , P , Aho , S , Moilanen , E , Alitalo , K & Kellokumpu-Lehtinen , P-L 2019 , ' High baseline Tie1 level predicts poor survival in metastatic breast cancer ' , BMC Cancer , vol. 19 , 732 . https://doi.org/10.1186/s12885-019-5959-8

Title: High baseline Tie1 level predicts poor survival in metastatic breast cancer
Author: Tiainen, Leena; Korhonen, Emilia A.; Leppänen, Veli-Matti; Luukkaala, Tiina; Hämäläinen, Mari; Tanner, Minna; Lahdenperä, Outi; Vihinen, Pia; Jukkola, Arja; Karihtala, Peeter; Aho, Sonja; Moilanen, Eeva; Alitalo, Kari; Kellokumpu-Lehtinen, Pirkko-Liisa
Contributor: University of Helsinki, CAN-PRO - Translational Cancer Medicine Program
University of Helsinki, CAN-PRO - Translational Cancer Medicine Program
University of Helsinki, HUSLAB
Date: 2019-07-24
Language: eng
Number of pages: 10
Belongs to series: BMC Cancer
ISSN: 1471-2407
URI: http://hdl.handle.net/10138/306047
Abstract: BackgroundAngiopoietin growth factors (Angs) regulate angiogenesis and lymphangiogenesis by binding to the endothelial Tie2 receptor. Ang2 expression is elevated in tissue hypoxia and inflammation, which also induce cleavage of the extracellular domain of the orphan Tie1 receptor. Here we have examined if the concentrations of Ang2 and the soluble extracellular domain of Tie1 in patient plasma are associated with the prognosis of patients with metastatic breast cancer.MethodsPlasma Tie1 and Ang2 levels were measured in metastatic breast cancer patients treated in a phase II trial with a taxane-bevacizumab combination chemotherapy in the first-line treatment setting. They were analyzed before treatment, after 6weeks and 6months of treatment, and at the final study visit. Using the median concentrations as cutoffs, Tie1 and Ang2 data were dichotomized into low and high concentration groups. Additionally, we analyzed Tie1 concentrations in plasma from 10 healthy women participating in a breast cancer primary prevention study.ResultsPlasma samples were available from 58 (89%) of the 65 patients treated in the trial. The baseline Tie1 levels of the healthy controls were significantly lower than those of the metastatic patients (p
Subject: Tie1
Angiopoietin-2
Angiogenesis
Metastatic breast cancer
Prognostic marker
RECEPTOR TYROSINE KINASE
PLUS WEEKLY PACLITAXEL
INHIBITS TUMOR-GROWTH
ANGIOPOIETIN-2 EXPRESSION
1ST-LINE BEVACIZUMAB
SERUM ANGIOPOIETIN-2
ANGIOGENESIS
PROGRESSION
ANTAGONIST
BIOMARKER
3122 Cancers
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s12885_019_5959_8.pdf 1.354Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record